Hospira Issues Nationwide Recall of Propofol Lot
Pfizer subsidiary Hospira has recalled one lot of its Propofol injectable emulsion due to visible particulates observed in two vials during an annual examination of retained samples.
Propofol is used in surgical procedures for the induction and maintenance of anesthesia or sedation. The affected products were distributed nationwide to wholesalers and hospitals from July 16, 2020 through July 24, 2020.
Patients receiving the impacted product have a remote risk of adverse events, such as blockage of blood vessels, including decreased blood flow to the brain, heart attack, pulmonary embolus and tissue necrosis. They are also at risk of hypersensitivity reactions.
Pfizer has not received reports of any adverse events associated with this issue for the lot so far.